Melphalan Zentiva

Melphalan, the active ingredient in Melphalan Zentiva, is an alkylating agent presented as a sterile solution for intravenous use. It is employed in the treatment of certain hematologic and solid tumors, including multiple myeloma and ovarian cancer, in adult oncology patients.

GNH USA supplies Melphalan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan Zentiva is an alkylating chemotherapy used for several malignant diseases: - Multiple myeloma: helps reduce malignant plasma cells and prolong remission. - Ovarian cancer: used in combination regimens to shrink tumor burden. - Melanoma: administered when other therapies are insufficient. - Thymoma: contributes to disease control in advanced stages. - Neuroblastoma: incorporated into pediatric protocols for high‑risk disease.

Melphalan may cause a range of adverse reactions. Monitoring and supportive care are essential.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during infusion. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related cancers. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: rare interstitial pneumonitis. - Renal impairment: occasional acute kidney injury.

Before initiating therapy, clinicians should assess patient suitability and monitor for complications. - Baseline labs: obtain complete blood count and renal function tests. - Infection risk: implement prophylactic measures and educate patients on signs of infection. - Pregnancy: avoid use in pregnant or nursing women unless benefits outweigh risks. - Drug interactions: review concomitant medications for potential additive toxicity. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antimetabolites (e.g., methotrexate): may amplify myelosuppression. - High‑dose radiation therapy: increases risk of severe tissue damage. - Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin): may reduce melphalan exposure. - Nephrotoxic agents (e.g., cisplatin): require renal function monitoring.